Duke University School of Medicine

A NIH-supported Phase 2b trial found that two doses of dalbavancin given seven days apart was equally effective as standard 4-6 week IV antibiotic therapy for complicated S. aureus bloodstream infections.

A new study reveals adalimumab demonstrates superior drug survival compared to infliximab in pediatric patients with hidradenitis suppurativa, contrasting with adult patient data.

Eledon Pharmaceuticals will present updated clinical data from approximately 30 kidney transplant recipients in their ongoing Phase 1b study of tegoprubart at the World Transplant Congress in San Francisco.

A retrospective study of 110 men with obesity or Type 2 diabetes found that GLP-1 receptor agonists like semaglutide and tirzepatide can naturally restore testosterone levels over 18 months of treatment.

New research from the University of Trieste shows prompt CPR initiation significantly improves cardiac arrest survival rates, regardless of whether performed by bystanders or medical professionals.

A Phase 2 multicenter trial found that transcranial direct current stimulation (tDCS) failed to enhance motor recovery when combined with constraint-induced movement therapy in post-stroke patients.

• A retrospective study revealed significant expression of FR-alpha (82.5%) and B7-H4 (82.1%) in endometrial cancer samples, highlighting potential new therapeutic targets for antibody-drug conjugate development. • High B7-H4 expression was predominantly found in low-grade endometroid disease, while elevated FR-alpha levels were more common in serous disease subtypes, suggesting distinct therapeutic approaches. • No tumor samples showed concurrent high expression of both FR-alpha and B7-H4, with HER2-negative tumors more likely to exhibit low or medium expression of both markers.

Advarra has integrated its electronic institutional review board (eIRB) system with Study Collaboration software, creating an automated connection between IRB review status and study startup workflows.

A study quantified time toxicity in lung cancer clinical trials, revealing a significant increase in time demands on patients from 2005-2024.

The REDUCE-AMI trial found no significant benefit in long-term beta-blocker treatment for patients with acute myocardial infarction (AMI) and preserved left ventricular ejection fraction (LVEF).